US Pharma MarketingSublingual semaglutide offered to UK practices despite Novo Nordisk concerns
Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Sublingual semaglutide, which does not hold marketing authorisation, is touted to minimise gastric issues.
Source: Pharmaceutical Technology